32953-13-2

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL-(3,4-DIMETHOXY-PHENYL)-AMINE is used as a chemical intermediate for the synthesis of novel fused tetrahydropyridine compounds. These compounds act as histone deacetylase (HDAC) inhibitors, which are important in the treatment and prophylaxis of HDAC-related diseases. HDAC inhibitors have shown potential in the treatment of various cancers, neurodegenerative disorders, and other diseases by modulating gene expression and altering chromatin structure.

Upstream product

• 64-17-5 ethanol 
• 6315-89-5 3,4-dimethoxyaniline 
• 75906-45-5 3',4'-dimethoxyacetophenone oxime 
• 62035-67-0 N-(3,4-dimethoxyphenyl)benzenesulfonamide 
• 91-16-7 1,2-dimethoxybenzene 
• 7368-78-7 4-bromoguaiacol 
• 893620-50-3 N-(3,4-dimethoxyphenyl)-N-ethylformamide 
• 331435-18-8 N-(3,4-dimethoxyphenyl)-2-nitrobenzenesulfonamide 
• 75-03-6 ethyl iodide 
• 66037-04-5 1-acetoxy-5-bromo-2-methoxybenzene 

Downstream Products

• 854819-00-4 ethyl-(3,4-dimethoxy-phenyl)-carbamoyl chloride 
• 32953-24-5 Diethyl-N-ethyl(3,4-dimethoxyanilino)methylenmalonat 
• 190842-57-0 2-[(3,4-dimethoxyphenyl)(ethyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one 
• 1386262-12-9 C₂₂H₂₂FNO₄S 
• 1386262-21-0 C₂₂H₂₂ClNO₄S 
• 1386261-93-3 C₂₃H₂₃NO₅S 
• 1386262-09-4 C₂₂H₂₃NO₄S 
• 1386262-07-2 C₂₃H₂₅NO₅S 
• 1333247-71-4 N-(3,4-dimethoxyphenyl)-N-ethyl-5-(hydroxy(phenyl)methyl)furan-2-carboxamide 
• 1311388-56-3 C₂₃H₂₃NO₅ 

Relevant academic research and scientific papers

N-substituted thiourea or urea derivatives and pharmaceutical composition for use in preventing or treating glutaminyl cyclase activity related diseases containing the same as an active ingredient

The N - substituted thiourea or urea derivative and the pharmaceutical composition for preventing or treating glutaminyl cyclase (QC) activity containing the same as an active ingredient. The phenylthiourea derivative according to the present invention bi

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease whose pathogenesis cannot be defined by one single element but consists of various factors; thus, there is a call for alternative approaches to tackle the multifaceted aspects of AD. Among the potential alternative targets, we aim to focus on glutaminyl cyclase (QC), which reduces the toxic pyroform of β-amyloid in the brains of AD patients. On the basis of a putative active conformation of the prototype inhibitor 1, a series of N-substituted thiourea, urea, and α-substituted amide derivatives were developed. The structure-activity relationship analyses indicated that conformationally restrained inhibitors demonstrated much improved QC inhibition in vitro compared to nonrestricted analogues, and several selected compounds demonstrated desirable therapeutic activity in an AD mouse model. The conformational analysis of a representative inhibitor indicated that the inhibitor appeared to maintain the Z-E conformation at the active site, as it is critical for its potent activity.

2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes

Based on our previous results on the ascertained potent growth inhibition effect against a panel of 60 human tumors cell lines at National Cancer Institute of Bethesda (NCI), we have synthesized a novel series of thirty-one 2-[N-methyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines (1-31). The lead compound 1 was previously reported to be endowed with significant inhibition against hDHFR enzyme, with a Ki of 0.2 μM. Docking studies were performed on compound 1 and here reported to predict its binding conformation to human dihydrofolate reductase (hDHFR). All compounds (1-31) were assayed versus hDHFR and human thymidylate synthase (hTS). From the screening emerged that all compounds inhibited hDHFR with Ki values included between 0.2 and 11 μM, while only a few (6, 21, 24, 27, 29) showed great activity and selectivity towards hTS. Evaluation of the anticancer activity was performed by NCI, first against the three cell line panel, and only the most active compounds (17, 21, 24, 26, 27) were evaluated on a panel of 60 human tumor cell lines. Compound 21 was the most active against all cell lines with log GI50 equal to -5.49 and log LC50 equal to -4.19 and maintained significant percent of growth inhibition on seven cancer cell lines at the concentration of 1 μM. Compound 17 was the second most active and moreover showed interesting selectivity against some cell lines (Lung cancer: A549/ATCC, Melanoma: UACC-257, Ovarian Cancer: ovcar-8 and Renal cancer: RXF 393) at all concentration examined (100-0.01 μM).

Fluorescent 6-hydroxy- and 6,7-dihydroxy-4-trifluoromethylcarbostyrils and formation of O-carboxymethylated derivatives via O-succinimide esters

(Chemical Equation Presented) Stepwise demethylation of fluorescent 6,7-dimethoxy-3-trifluoromethylcarbostyrils 5 leads to 6-hydroxy derivatives 6 and 6,7-dihydroxyderivative 7. Phenolate formation shifts excitation and emission maxima from 370 and 430 nm to 430 and 480 nm for the anion of 6 and as far as 500 and 580 nm for the dianion of 7. Dependence of fluorescence quantum yield on media and polar structure, varying from 0.02 to 0.51, is discussed. O-Alkylation of 6 with alkyl bromoacetate yields esters of type 8 in good yield. Reactive succinimidoyl (OSu) esters of type 11 were prepared after saponification to acids 9. With amino acids or their esters, peptides and aminoglucose, linking to labeled derivatives 13 or 15 could be achieved under mild conditions in slightly basic aqueous media.

DIISOBUTYLALUMINIUM HYDRIDE A NOVEL REAGENT FOR THE REDUCTION OF OXIMES

A simple procedure for converting oximes to rearranged secondary amines is described.